Study of the effect of vitamin D supplementation on glycemic control in type 2 diabetic prevalent hemodialysis patients.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The aim of this study was to assess the possible effect of short-term alfacalcidol supply on glycemic control in type 2 diabetic hemodialysis (HD) patients.

Why It Was Studied

Vitamin D is claimed to have an adjuvant effect on glycemic control by dual action on pancreatic β-cells and insulin resistance.

Twenty type 2 diabetic HD patients (using diet and oral drugs but not insulin) were randomly selected from their dialysis unit as well as 20 non-diabetic HD patients as control.

Who Took Part

The study group was 2 patients.

The age groups tagged for this paper are middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Dietary Supplements, Renal Dialysis, Vitamin D and Vitamin D Deficiency.

The authors tagged it with the keywords glucoparameters, hemodialysis and type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2015 (Hemodialysis international. International Symposium on Home Hemodialysis), a journal based in Canada.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.